Check out our newest paper on risk factors for BCR after PSMA-guided RT in de novo lymph node positive #prostatecancer in Frontiers - Oncology! 👉🏼 > 2 nodes associated with worse bRFS 👉🏼 high SUVmax associated with worse MFS #radonc Constantinos Zamboglou Uniklinik Freiburg doi.org/10.3389/fonc.2…

A new report from Shankar Siva shows why TOTAL METASTATIC ABLATION is preferred whenever feasible. #radonc 1/

63% pCR rates after neoadjuvant Nivo/Ipi cCRT in T3-4 N0-2 NSCLC (Increase trial) #ESMO. I wonder what the pCR rates would be after defintive immuno-chemo-radiotherpy.

1/ I wonder why we find the key quality indicators in Checkmate 816 of “surgical outcomes” on pg36 of the supplement T5? Importantly, 30-day mortality and rate of R0 resection seem worse than 6 other neoadjuvant studies. #radonc #tssmn The Society of Thoracic Surgeons CTSurgSocMedNetwork

2/ elegantly query by Chris Cao in letter to editor - bit.ly/3BTV1ZK. We need to be carefully selecting patients for neoadj. ChemoIO if it risks early death or needing PORT Jonathan Spicer MD PhD Patrick Forde H. Jack West, MD, FASCO Sanjay Popat Drew Moghanaki 🐕 Brendon Stiles

COAST: Durvalumab alone or in combination with Oleclumab or Monalizumab in unresectable stage III NSCLC after RCT ORR: 17.9 % vs 30.0% 35.5% 12 mo PFS: 34% vs 63% vs 73% 👉 promising data to go beyond PACIFIC #radonc ascopubs.org/doi/pdf/10.120…

Review of pathologic complete response (pCR) shows that evidence currently available does not support pCR used alone as a reliable surrogate endpoint in neoadjuvant randomized controlled trials for breast cancer. ja.ma/3En94dh #BCSM

Presented at #ESMO22 ESMO - Eur. Oncology, now in our Oct issue: interim analysis of PEARLS/KEYNOTE-091: #pembrolizumab vs placebo as #adjuvant therapy for completely resected stage IB–IIIA non-small-cell #lungcancer #NSCLC thelancet.com/journals/lanon…

This #SpecialCommunication presents a prioritized list of recommended terms for inclusion and exclusion criteria in first-line, therapeutic clinical trials for advanced non–small cell lung cancer that are intended to support marketing application. ja.ma/3RNjTcm

In pts w limited brain mets after surgical resection, secondary analysis of rand phase 3 trial shows more patients declined significantly in 1 or more cognitive tests with whole brain radiation therapy (WBRT) vs stereotactic radiosurgery (SRS) ja.ma/3Ty6NA6 #BTSM

ESTRO-ACROP Delphi consensus paper Recommendations for radiation therapy in oligometastatic prostate cancer Thomas Zilli et al. doi.org/10.1016/j.rado… thegreenjournal.com/article/S0167-…

Today is Day 1 of Lung Cancer Awareness Month 2022 (#LCAM22). Fact: Did you know that #LungCancer causes more deaths globally than colon, breast, & prostate cancers combined? #LCSM

Check out our paper in IJROBP - The Red Journal on genomic classifiers in personalized RT of #prostatecancer. We conducted a systematic review and delphi consensus with experts across the world! Focusing on the setting of RT this paper is for the #radonc and #GU cancer community

Neo-AEGIS: FLOT v CROSS for esoph/GEJ (n=362) 362 pts. No dif in 3-yr OS (57% v 55%), though path outcomes improved w chemoRT. Not surprised that for all-comers no dif, clearly not one size fits all. Interested in future studies of chemo-->chemoRT-->surg. #GI23 OncoAlert

The latest publication from our division of radiobiology delivers new insights into the immunogenic effect of Cisplatin ➡️Cisplatin enhanced the absopcal effect more stronlgy than oxaliplatin or carboplatin ➡️Cisplatin induces antitumour immunity through necroptosis-mediated ICD

🚨OPERA Results are out 👉 148 rectal cancer patients rand to 45 Gy + 9 Gy or 45 Gy + 3 x 30 Gy (!!!) using Papillon 👉 Patients with early rectal tumors, Max cT3b 👉 An incredible organ preservation rate! bit.ly/3J9Eohi Congratulations to JP Gerard and Sun Mynt. #radonc

Check out the latest paper by Gkika Eleni Elke Firat Simon Lo NilsNicolay Dan Duda Anca-L. Grosu, MD Great collaboration with Edwin L. Steele Laboratories on the first results of the LAPIS trial published in npj Journals precision oncology. nature.com/articles/s4169… #lungcancer

Stereotaktische Strahlentherapie bietet neue Behandlungsoption für Patient:innen mit austherapierten ventrikulären Tachykardien – Zwischenergebnisse der deutschen multi-zentrischen RAVENTA-Studie - dgk.org/pressemitteilu…